- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Breast MR beats mammo, ultrasound for women with nipple discharge
In women with nipple discharge, contrast breast MR has higheroverall sensitivity for detecting malignant and high-risk lesionsthan mammography or ultrasound.
In women with nipple discharge, contrast breast MR has higher overall sensitivity for detecting malignant and high-risk lesions than mammography or ultrasound.
Between March 2007 and July 2009, 38 women with nipple discharge underwent ultrasound, mammography, and contrast MR (1.5T). A malignant lesion was found in five of 38 patients. A high-risk lesion was found in 14 of 38 patients. Contrast MR found all five of the cancers and 13 of the 14 high-risk lesions for a sensitivity of 94.74%. Mammography had a sensitivity of 26.32%; ultrasound had a sensitivity of 63.16%.
Contrast MR should be recommended when conventional imaging is negative, according to Dr. Michele Lorenzon, from the radiology department at the University of Udine in Italy. The study was presented at the European Congress of Radiology in Vienna in March.
Can Radiomics and Autoencoders Enhance Real-Time Ultrasound Detection of Breast Cancer?
September 10th 2024Developed with breast ultrasound data from nearly 1,200 women, a model with mixed radiomic and autoencoder features had a 90 percent AUC for diagnosing breast cancer, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Predicting DCIS Upgrade to Invasive Breast Cancer: Can Contrast-Enhanced Ultrasound Have an Impact?
August 21st 2024Adding two key findings from contrast-enhanced ultrasound to a predictive model of mammography, conventional ultrasound and clinicopathological findings led to a 86.1 percent AUROC for predicting the upgrading of ductal carcinoma in situ to invasive breast cancer, according to new research.
FDA Clears AI-Powered Cardiovascular Ultrasound System from Siemens Healthineers
August 13th 2024Offering a variety of AI features for streamlined workflow and enhanced visualization, the Acuson Origin ultrasound system also features the newly FDA-cleared AcuNav Lumos 4D ICE (intracardiac echocardiography) catheter.
